US Patent IssuedNew Zealand Pharmaceuticals Ltd is pleased to announce that the U.S. patent 8,420,063,…
Application of N-acetylmannosamineThe application of N-acetylmannosamine to the mammalian cell culture production of…
NZP is certified ISO 14001New Zealand Pharmaceuticals Ltd is proud to announce that is has been audited by TELARC…
|
We are pleased to announce that Dextra laboratories Ltd and NZP will attend Informex USA 2013 in Anaheim CA, on February 20 & 21, 2013.
Please arrange to meet us by direct email contact to
This email address is being protected from spambots. You need JavaScript enabled to view it.
, to discuss the supply of API cGMP bile acids, nucleosides and carbohydrate derivatives for pre-clinical or clinical trials, custom synthesis, blood purification products and glycobiology products.
All preparations can be developed from concept through to Phase II at the Dextra, Reading, UK site and larger scale manufacturing undertaken at NZP. NZP manufactures large volumes of the key bile acid, cholic acid, bile acid derivatives and GMP quality ManNAc.
NZP produces of a range of bulk pharmaceutical intermediates and pharmaceutical ingredients for supply to pharmaceutical and biotechnology companies worldwide.
These bile acids have gained popularity with assistance to solubilise non-polar drugs for delivery in aqueous media by injection.
NZP manufactures several refined bile products that are used as selective inhibitory agents in bacteriological media. These include pure sodium salts of bile acids, which are supplied to biotech and media companies worldwide.
NZP’s sister company, Dextra located in Reading, UK, undertakes custom carbohydrate synthesis and offers a catalogue of carbohydrate derivatives for glycobiology and other applications.
NZP manufactures a range of dietary supplement ingredients under GMP conditions.
In consultation with the aquaculture industry, NZP has developed Mixed Bile Acids, which is easily incorporated into feeds.